jama glp-1 Glucagon-like peptide-1 (GLP-1) receptor agonists (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are medications that reduce food cravings, increase fullness, slow digestion, and can help control Integrating lifestyle factors like diet

Present and Future of Weight Loss It may be possible to maintain weight loss while tapering GLP-1 to a lower dosage or prolonging the time between doses [276,277]

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), completed in 2023 with over 17,600 participants, demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity but without diabetes

SS Korsakova

Think of it like this your kidney becomes a sugar drain

Considering Pituitary Reserve Limitations Some patients simply lack adequate remaining pituitary function for meaningful Sermorelin response regardless of dose optimization